Key takeaway: The investor presentation by Cosmo First Limited detailed the company's operational and financial performance for the quarter ended June 30, 2026. Management reported a strategic shift from an investment phase to value creation, highlighting over ₹1,200 crore in strategic capex completed in the last three years. The company achieved a revenue CAGR of 19% and an EBITDA CAGR of 38% from FY24 to FY26. Key business segments, including Cosmo Films and Specialty Chemicals, showed significant growth, with Cosmo Films reporting a 45% YoY revenue increase in Q1 FY27. Management noted a focus on increasing specialty films volume and improving capacity utilization across all B2B businesses. The presentation also emphasized the company's commitment to reducing net debt to below 2.0x EBITDA within 12-18 months. Overall, the document outlined a positive trajectory in revenue and profitability across various business segments.

Key takeaway: Management reported that consolidated sales for Q4 FY26 reached Rs 1,021 crores, a 37% increase from Q4 FY25, driven by a 41% rise in volume. EBITDA for the quarter rose by 53% to Rs 130 crores, attributed to higher sales volume and improved margins in BOPP and BOPET. For the full year, revenue increased by 26%, with EBITDA up 32% to Rs 479 crores. Management set a goal of double-digit topline growth for the Film business in FY27, supported by enhanced capacity utilization. The Specialty Chemicals subsidiary achieved sales of Rs 54 crores in Q4, with a 25%+ EBITDA margin. Management noted a focus on reducing net debt and emphasized the importance of intrinsic value growth across business verticals. A dividend of Rs. 4 per equity share was proposed, subject to shareholder approval.

Key takeaway: The investor presentation by Cosmo First Limited detailed the company's operational and financial performance for the quarter and year ended March 31, 2026. Management reported a strategic shift from an investment phase to value creation, highlighting a completed capex cycle of over ₹1,200 crore in the last three years. The company achieved a revenue CAGR of 19% and an EBITDA CAGR of 38% from FY24 to FY26. Key business segments included flexible packaging films, specialty chemicals, and consumer products, with significant revenue growth reported across these areas. The presentation noted a reduction in net debt by ₹75 crore and a focus on achieving full capacity utilization in various business segments. Management also announced a dividend of ₹4 per equity share, subject to shareholder approval. The document emphasized the company's commitment to sustainability and innovation, with ongoing investments in R&D and a strong ESG framework.

Key takeaway: Cosmo First Limited held an earnings call on February 12, 2026, to discuss its Q3 and nine-month FY26 results. Management reported a consolidated sales increase of 28% year-over-year to ₹899 crores, driven by a 29% rise in volume. EBITDA rose by 19% to ₹103 crores, aided by higher sales volume and improved specialty margins. However, EBITDA was negatively impacted by several factors, including a decline in BOPP film margins due to increased imports and high USA tariffs. Management noted a plan to reduce net debt over the next 2-3 years, with no major capex planned. The specialty chemicals segment showed growth, with sales of ₹52 crores and a 25% EBITDA margin. The company aims for double-digit revenue growth in upcoming quarters, supported by enhanced capacity utilization and a reduction in USA tariffs. Management emphasized a focus on intrinsic value growth across business verticals.

Key takeaway: The investor presentation from Cosmo First Limited detailed the company's operational and financial performance for the quarter ended December 31, 2025. Management reported that the strategic capital expenditure of INR 1,140 crore has been largely completed, with a focus now on cash generation and improving return on capital employed (ROCE). The presentation highlighted a structural shift towards a higher-margin specialty portfolio, emphasizing R&D and innovation. Management noted that the EBITDA improved due to higher sales volume and better performance from the specialty chemicals subsidiary. However, challenges included margin declines in core films and inventory losses. The company aims to enhance capacity utilization and scale new businesses, particularly in the pet care and consumer segments. The document also outlined a clear roadmap for reducing net debt over the next two years, with no significant capex planned ahead.